12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Phase II data

Top-line data from the open-label, international Phase II PXD101-CLN-17 in 89 patients with previously untreated CUP showed that belinostat plus carboplatin and paclitaxel missed the primary endpoint of PFS vs. carboplatin and paclitaxel alone (5.4 vs. 5.3 months, p=0.5526). Belinostat plus chemotherapy did meet the secondary endpoint of improving ORR vs. chemotherapy alone (43.2% vs. 22.2%, p=0.0252), but non-significantly improved...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >